114786-39-9 Usage
Uses
Used in Pharmaceutical Research and Development:
(S)-Methyl 4,5,6,7-tetrahydro-3h-iMidazo[4,5-c]pyridine-6-carboxylate DiHCl is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique molecular structure allows for the development of new drugs with potential therapeutic applications.
Used in Medical Applications:
As a compound with potential pharmacological properties, (S)-Methyl 4,5,6,7-tetrahydro-3h-iMidazo[4,5-c]pyridine-6-carboxylate DiHCl is used for further investigation into its possible therapeutic uses in the field of medicine. Its properties may contribute to the development of novel treatments for various medical conditions.
Used in Chemical Synthesis:
In the chemical industry, (S)-Methyl 4,5,6,7-tetrahydro-3h-iMidazo[4,5-c]pyridine-6-carboxylate DiHCl is used as a key component in the synthesis of other complex molecules, contributing to the creation of new compounds with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 114786-39-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,4,7,8 and 6 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 114786-39:
(8*1)+(7*1)+(6*4)+(5*7)+(4*8)+(3*6)+(2*3)+(1*9)=139
139 % 10 = 9
So 114786-39-9 is a valid CAS Registry Number.
114786-39-9Relevant academic research and scientific papers
JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
-
Page/Page column 39; 40, (2018/09/28)
The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
INHIBITORS OF THE HIV INTEGRASE ENZYME
-
Page/Page column 76, (2008/06/13)
The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE
-
Page 57, (2010/02/06)
Bicyclic hydroxamate compounds represented by the Formula I are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated dise
